This invention relates to antisense oligonucleotides directed against the mRNA of the corticotropin releasing factor subtype-2 (CRF2) receptor which substantially reduce expression of CRF2 receptors in the rodent brain and the use of antisense oligonucleotides in vivo CNS studies of gene function and to treat a wide range of psychiatric disorders including anxiety, obsessive-compulsive disorder, panic disorders, post-traumatic stress disorders, phobias and depression. 27 claims, 6 figures
CRF2 LIGANDS IN COMBINATION THERAPY